echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Simcere Pharmaceuticals obtains exclusive rights to anti-cancer drug paxalisib in Greater China

    Simcere Pharmaceuticals obtains exclusive rights to anti-cancer drug paxalisib in Greater China

    • Last Update: 2021-04-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On March 29, Simcere Pharmaceuticals announced that its subsidiary has signed an exclusive license agreement with Kazia Therapeutics, an Australian oncology drug development company, to introduce the anti-cancer drug paxalisib under investigation in Greater China (Mainland China, Hong Kong, Macau and Taiwan).


    Paxalisib is a PI3K/mTOR pathway inhibitor with high blood-brain barrier penetration.


    According to the agreement, Simcere will be responsible for the development, registration and commercialization of paxalisib in the Greater China region.


    Organized from: Simcere Pharmaceutical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.